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Abstract The molecular mechanism that regulates iron ho-
meostasis is based on a network of signals, which reflect on
the iron requirements of the body. Hereditary hemochromatosis
is a heterogenic metabolic syndromewhich is due to unchecked
transfer of iron into the bloodstream and its toxic effects on
parenchymatous organs. It is caused by the mutation of genes
that encode proteins that help hepcidin to monitor serum iron.
These proteins include the human hemochromatosis protein -
HFE, transferrin-receptor 2, hemojuvelin in rare instances, and
ferroportin. HFE-related hemochromatosis is the most frequent
form of the disease. Interestingly, the low penetrance of poly-
morphic HFE genes results in rare clinical presentation of the
disease, predominantly in middle-aged males. Taking into ac-
count the wide dispersion of HFE mutation in our population
and also its unknown role in heterozygotes, we analyzed the
impact of H63D HFE carriage in the developmental age, with
respect to gender, on the iron status and hemoglobin concen-
tration of carriers in comparison to those of wild-typeHFE gene
(12.7 ± 3.07 years, 42 boys and 41 girls). H63D carriers pre-
sented higher blood iron, transferrin saturation, and ferritin con-
centration than wild-type probands (p < 0.05.) Interestingly,
male H63D carriers showed higher hemoglobin concentration
than the unburdened children. Moreover, in the H63D carrier
group, a positive correlation between iron and hemoglobin was
noted. In conclusion, this study demonstrates that changes in
iron metabolism occur at a young age in HFE heterozygotes.
Keywords Children . HFEmutation . Iron . Ferritin .
Transferrin saturation . Hemoglobin
Introduction
Hereditary hemochromatosis is an autosomal recessive dis-
order associated with increased intestinal absorption of di-
etary iron and deposition of excessive amounts of iron in the
liver, pancreas, and other organs [1, 2]. The syndrome is a
result of genetically determined failure to stop iron entering
the circulatory pool when it is not needed. It is associated
with several pathogenic mutations of at least five genes
(HFE, TfR2, HJV, HAMP, and SLC40A1), and it is likely
due to a regulatory defect in iron homeostasis [3, 4]. HFE-
related hemochromatosis is the most common genetic dis-
order in northern European populations with a prevalence of
1:200 to 1:250 for homozygosity and a carrier rate of 1:8 to
1:12 [5, 6]. C282Y polymorphism of the HFE gene is par-
ticularly associated with disease development. In the
abovementioned populations, simple H63D heterozygosity
occurs in a t l eas t 23 .6–31 .1 % [7] . Hered i t a ry
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The impact of H63D HFE gene carriage on hemoglobin and iron
status in children
hemochromatosis is characterized by enhanced intestinal
absorption of iron and its excess accumulation resulting in
multiple organ damage, such as cirrhosis, hepatoma, diabetes
mellitus, arthritis, and cardiomyopathy. The symptomatic phe-
notype preceded by fatigue, arthropathy, and impotence occurs
predominantly in males between the fourth and sixth decades of
life, depending on gene penetration and multiple concomitant
factors in C282Y homozygotes, in some cases H63D/C282Y
compound heterozygotes, and occasionally H63D homozy-
gotes [1, 8]. HFE gene mutation impact on iron accumulation
during the clinical course of hemochromatosis is unpredictable
due to reduced gene penetration and coincidence of concomi-
tant endogenic, environmental, and other unknown factors
[9–12]. However, HFE homozygotic and even heterozygotic ge-
notypes might be associated with disease progression in the pres-
ence of concomitant diseases. The clinical impact of HFE muta-
tion per se still remains unknown. Notably, since iron accumula-
tion is a prolonged process, iron overload is rarely observed in
children [13]. Therefore, the developmental population seems to
be a promising group to make preliminary observations consid-
ering possible HFE gene impact on future iron storage. In our
presented investigations, we compared iron metabolism in the
developmental age, with respect to gender, of H63D carriers with
that of the wild-type group. Moreover, taking into consideration
the role of iron in hematopoiesis, we analyzed hemoglobin con-
centration in particular groups. Iron, ferritin concentration, and
transferrin saturation were statistically higher in both H63D gen-
der groups.Moreover, hemoglobin concentrationwas statistically
higher in male H63D carriers than in other groups. Remarkably,
the H63D group presented with a statistically significant positive
correlation between iron and hemoglobin concentration.
Material and methods
Eighty-three, i.e., nonkindred children of Polish origin
aged 12.7 ± 3.07 (42 boys and 41 girls), were considered
for the study. Fifty children, aged 12.6 ± 2.41 (25 boys and 25
girls) presented with wild-type HFE gene, whereas 33
children, aged 12.8 ± 3.95 (17 boys and 16 girls), were carriers
of HFE H63D mutation (data presented in Table 1). Patients’
BMI did not differ statistically. In order to exclude acute and
chronic illnesses, or internal organ insufficiency, all patients
underwent physical examination, laboratory assays
which included a full blood count with reticulocytosis
and microscopic evaluation, protein C concentration, as-
partate and alaninie transaminase activities, bilirubin,
creatinine levels, HBsAg, and anti-HCV antibodies.
Iron metabolism was also assessed by measuring iron
concentration, ferritin levels, and transferrin saturation
(SYSMEX XE 2100, Architect ci 8200, and Test 1 SDL).
Abdominal ultrasound was also performed and did not reveal
any abnormalities. Patients underwent genetic testing for
HFE mutations (H63D S65C C282Y), which was per-
formed using real-time PCR. The study was officially
approved by the Bioethical Committee of the Regional
Medical Society in Gdansk NKBBN/409/2013 in accord
with the Helsinki Declaration.
Statistical analysis
Statistical analysis of the data included Student’s t tests for
independent samples to compare categorical variables
between wild-type and H63D mutation groups. Differences
between gender subgroups of wild-type and H63D mutation
groups were calculated with nonparametric Kruskal-Wallis
unpaired test. Correlations between iron concentration and
hemoglobin were examined by Pearson’s correlation coeffi-
cient. Values of p ≤0.05 were considered statistically signifi-
cant. Calculations were performed using Statistica 10.0
(StatSoft 2011) (References StatSoft, Inc. (2011);
STATISTICA (data analysis software system), version 10;
www.statsoft.com).
Table 1 Anthropometric
characteristics of the subjects Mutation Age (years) Weight (kg) Height (cm) BMI (kg/m
2)
Wild type F (n = 25) 12.1 ± 2.62 42.1 ± 14.1 149.8 ± 3.3 18.3 ± 3.63
M (n = 25) 13.2 ± 2.11 51.3 ± 16.1 159.8 ± 15.9 19.6 ± 3.19
All (n = 50) 12.6 ± 2.41 46.7 ± 15.7 154.8 ± 15.3 19.0 ± 3.45
H63D F (n = 16) 12.0 ± 4.43 40.6 ± 20.8a 147.1 ± 22.5c 17.6 ± 5.26
M (n = 17) 13.6 ± 3.39 57.8 ± 19.8b 164.8 ± 20.5 20.4 ± 4.11
All (n = 33) 12.8 ± 3.95 49.5 ± 21.8 156.2 ± 23.0 19.1 ± 4.84
Results are shown as means ± SD
F female, M male, n numbers, BMI body mass index
Statistical significant difference:
Weight; a H63D_F/H63D_M, p = 0.0306; b H63D_M/WT_F, p = 0.0468
Height; c H63D_F/H63D_M, p = 0.0288
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Results
In the entire group of tested children, the mean concen-
tration of iron, ferritin, and transferrin saturation were
within normal range (mean values: iron 119.9 μg/dl, SD
48.8; ferritin 32.0 ng/ml, SD 19.0; TIBC 224.9 μg/dl, SD
77.4; and transferrin saturation Ts 32.6 %, SD 13.7). The
wild-type HFE gene group (WT group) presented with a
mean iron concentration of 99.1 μg/dl, SD 30.7; ferritin
28.3 ng/ml, SD 15.7; TIBC 273.4 μg/dl, SD 45.6; and
transferrin saturation 27.1 %, SD 8.3. The H63D mutation
carrier group presented with a mean iron concentration of
151.5 μg/dl, SD 54.3; ferritin concentration 37.6 ng/ml,
SD 22.1; TIBC 151.5 μg/dl, SD 54.3; and transferrin
saturation of 40.9 %, SD 16.1. All the values were statis-
tically higher in the entire H63D carrier group, compared
to the wild-type group except for TIBC which was statis-
tically lower (data presented in Table 2). Interestingly,
hemoglobin concentration and hematocrit levels of the
entire H63D carrier group was statistically higher than
that of the wild type, while a similar relation was not
observed in red blood cell number. Notably, there were
some other phenomena noted regarding gender groups
such as male H63D carriers having statistically higher
iron concentration than female H63D carriers and both
WT males, and females as well. In addition, female
H63D carriers had statistically higher iron concentration
than WT females. Male H63D carriers presented with a
statistically lower TIBC and a statistically higher trans-
ferrin saturation than both WT gender groups. Female
H63D carriers had statistically lower TIBC than both
WT gender groups. Hemoglobin concentration of male
H63D carriers was statistically higher than that of the
other groups. Male H63D carriers presented with a
higher red blood cell count than both female groups
and higher hematocrit levels than WT female group
(data presented in Table 3). Statistically significant pos-
itive correlation between iron and hemoglobin concen-
tration was noted in the entire H63D group compared
with the healthy group, whereas with respect to gender
groups (male and female H63D carriers compared to
healthy controls), such phenomenon was not noted (data
presented in Figs. 1 and 2, Tables 4 and 5).
Table 2 Iron status parameters in control and H63D mutation group
Variables All (n = 83) WT (n = 50) H63D (n = 33) p value
Fe (μg/dl) 119.9 ± 48.8 99.1 ± 30.7 151.5 ± 54.3 0.0000a
Ferritin (ng/ml) 32.0 ± 19.0 28.3 ± 15.7 37.6 ± 22.1 0.0425a
Ts (%) 32.6 ± 13.7 27.1 ± 8.31 40.9 ± 16.1 0.0000a
Hb (g/dl) 14.2 ± 1.30 13.8 ± 0.99 14.8 ± 1.47 0.0018a
RBC (ml/dl) 4.93 ± 0.45 4.86 ± 0.39 5.02 ± 0.52 0.1305
Ht (%) 42.1 ± 5.70 40.5 ± 2.76 44.4 ± 7.90 0.0015a
TIBC 224.9 ± 77.4 273.4 ± 45.6 151.5 ± 54.3 0.0000a
Results are shown as means ± SD
WTwild type, Fe iron, Ts transferrin saturation, Hb hemoglobin concen-
tration, RBC red blood cells, Ht hematocrit, TIBC total iron-binding
capacity
a Statistical significant difference
Table 3 Iron status parameters in
female and male of control and
H63D mutation groups
Variables WT_F (n = 21) WT_M (n = 39) H63D_F (n = 27) H63D_M (n = 31)
Fe (ug/dl) 93.9 ± 26.8 104.4 ± 33.9 134.0 ± 52.6a 167.9 ± 52.0b,c
Ferritin (ng/ml) 28.7 ± 16.2 27.8 ± 15.6 32.7 ± 19.8 42.1 ± 23.7
Ts (%) 27.1 ± 7.83 27.0 ± 8.93 36.8 ± 15.0 44.7 ± 16.6b,c
Hb (g/dl) 13.4 ± 0.74 14.2 ± 1.08 13.9 ± 0.90d 15.7 ± 1.43b,c
RBC (ml/dl) 4.68 ± 0.35 5.05 ± 0.33e 4.73 ± 0.47d 5.30 ± 0.41b
Ht (%) 39.6 ± 2.08 41.5 ± 3.04 43.3 ± 10.8 45.4 ± 3.72b
TIBC 266.9 ± 7.5 279.8 ± 43.6 134.0 ± 52.6f,a 167.9 ± 52.0b,c
Results are shown as means ± SD
WT_F wild type female, WT_M wild type male, H63D_F H63D female, H63D_M H63D male, Fe iron, Ts
transferrin saturation, Hb hemoglobin concentration, RBC red blood cells, Ht hematocrit, TIBC total iron-binding
capacity
Statistical significant difference:
Fe; a H63D_F/WT_F, p = 0.0320; b H63D_M/WT_F, p = 0.0002; c H63D_M/WT_M, p = 0.0002
Ts; b H63D_M/WT_F, p = 0.0004; c H63D_M/WT_M, p = 0.0004
Hb; dH63D_F/H63D_M, p = 0.0002; b H63D_M/WT_F, p = 0.0001; c H63D_M/WT_M, p = 0.0006
RBC; dH63D_F/H63D_M, p = 0.0005; b H63D_M/WT_F, p = 0.0002; eWT_F/WT_M, p = 0.0048
Ht; bH63D_M/WT_F, p = 0.0124
TIBC; f H63D_F/WT_M, p = 0.0001; a H63D_F/WT_F, p = 0.0001; b H63D_M/WT_F, p = 0.0001; c H63D_M/
WT_M, p = 0.0001
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Discussion
The impact of the HFE gene mutation on biochemical
features of homozygotic and heterozygotic adults seems
to be intelligible [2, 9–11, 14]. The diversity and frequen-
cy of gene mutation among populations provide a broad
range of biochemical and occasionally clinical symptoms.
However, the course of hemochromatosis is unpredictable
since reduced gene penetration and possible concomitant
environmental and epigenetic factors also play a role in
disease development or progression [15, 16]. Therefore,
knowing the HFE status of a child together with a precise
analysis and follow-up of iron metabolism could identify
an affected person who could potentially demonstrate
clinical phenotype. In the current study, we compared iron
metabolism of H63D HFE gene carriers, as it is the
commonest in our population, with that of healthy chil-
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Fig. 1 Correlation between iron
and hemoglobin concentration.
H63D group presented with
statistical significant positive
correlation. Wild-type group
(WT): y = 13.4254 + 0.0036*x;
r = 0.1125; p = 0.4368;
r2 = 0.0126. Carriers group
(H63D): y = 13.0201 +
0.0119*x; r = 0.4382;
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Fig. 2 Correlation between iron
and hemoglobin concentration in
gender groups. There were no
statistical differences. Wild-type
female group (WT_F):
y = 13.2572 + 0.0016*x;
r = 0.0580; p = 0.7832;
r2 = 0.0034. Wild-type male
group (WT_M): y = 14.0069 +
0.0015*x; r = 0.0473; p = 0.8225;
r2 = 0.0022. Carriers male group
(H63D_M): y = 13.4959 +
0.0128*x; r = 0.4658; p = 0.0595;
r2 = 0.2170. Carriers female
group (H63D_F): y = 13.6595 +
0.0021*x; r = 0.1208; p = 0.6559;
r2 = 0.0146
2046 Ann Hematol (2016) 95:2043–2048
significantly higher iron, ferritin concentration, and trans-
ferrin saturation in H63D carrier group. Interestingly, all
the parameters were higher in heterozygotes of both gen-
ders. This supports previous studies that involved HFE
polymorphism and its biochemical impact on altered iron
metabolism in childhood [17–19]. However, pathological
iron loading in primary hemochromatosis is a prolonged
and unpredictable process, affected by additional, innate
and acquired conditions [1–4]. Results obtained in the
present study suggest the need for genotyping chosen
subjects from the developmental age. Moreover, an
analysis performed on the association of iron and hemo-
globin concentration revealed a positive correlation in
HFE carrier group. Knowing the undoubted role of this
trace element in hematopoiesis, our observations under-
line its unique impact on variant H63D carriers. The
influence of unstable iron homeostasis on erythropoiesis
modulation intensity by direct or indirect mediators of the
metabolic pathways cannot be excluded [20, 21].
However, the HFE group presented with a positive iron-
hemoglobin correlation, only male HFE carriers had
statistically higher hemoglobin concentration compared
to the other groups, presumably due to the direct effects
of pubertal androgens [22].
Expertise on congenital hemochromatosis in children
is limited; hence, recording and monitoring of any clin-
ical or laboratory abnormalities in these probands seems
to be justified.
Conclusion
H63D variant of HFE gene increased iron absorption and
present a positive impact on erythropoiesis modulation
in children.
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